title: Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity.
abstract: Oncolytic viruses, proteasome inhibitors, and natural killer (NK)-cell immunotherapy have all been studied extensively as monotherapies but have never been evaluated in combination. Synergetic treatment of oncolytic virus-infected glioblastomas with a proteasome inhibitor induces necroptotic cell death to enhance NK-cell immunotherapy, prolonging survival against human glioblastoma. Clin Cancer Res; 22(21); 5164-6. ©2016 AACRSee related article by Yoo et al., p. 5265.
authors: Department of Neurosurgery, Duke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.|The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.|Department of Pathology, Duke University Medical Center, Durham, North Carolina.
authors: Carter M
authors: CM
authors: Suryadevara
authors: Department of Neurosurgery, Duke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina.|The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.|Department of Biomedical Engineering, Duke University, Durham, North Carolina.
authors: Katherine A
authors: KA
authors: Riccione
authors: Department of Neurosurgery, Duke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, North Carolina. john.sampson@duke.edu.|The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.|Department of Pathology, Duke University Medical Center, Durham, North Carolina.|Department of Biomedical Engineering, Duke University, Durham, North Carolina.
authors: John H
authors: JH
authors: Sampson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069286:Bortezomib / Q000627:therapeutic use*; D016923:Cell Death / Q000187:drug effects / Q000276:immunology; D003131:Combined Modality Therapy / Q000379:methods; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D005909:Glioblastoma / Q000188:drug therapy / Q000276:immunology*; D018259:Herpesvirus 1, Human / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D050130:Oncolytic Virotherapy / Q000379:methods; D050504:Oncolytic Viruses / Q000276:immunology*; D061988:Proteasome Inhibitors / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D061988:Proteasome Inhibitors; D000069286:Bortezomib